MVIR — Medivir AB Share News
0.000.00%
Last trade - 00:00- SEK906.04m
- SEK763.34m
- SEK8.51m
Brief: Medivir And SciLifeLab Enter Collaboration On Potential SARS CoV-2 Inhibitors
Brief: Medivir: European Commission Grants Orphan Medicinal Product Designation In EU For MIV-818
Brief: Medivir Appoints Yilmaz Mahshid As New CEO
Brief: Medivir: FDA Grants MIV-818 ODD For The Treatment Of Hepatocellular Carcinoma
Brief: Medivir Q1 EBITDA Loss Narrows To SEK 20.7 Million
Brief: Medivir Receives Positive Opinion On Orphan Medicinal Drug Designation By The European Medicines Agency For Miv-818
Brief: Medivir Chief Medical Officer Leaves
Brief: Medivir: Positive Data From Completed Phase Ia Study With MIV-818 In Patients With Advanced Liver Cancer
Brief: Medivir And Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement
Brief: Medivir Q4 EBITDA Loss Narrows To SEK 30.3 MIllion
Brief: Medivir Receives Notices Of Allowance In EU And Japan For MIV-818 Patent Applications
Brief: Medivir To End Study With Birinapant, Keytruda In Colorectal Cancer Patients
Brief: Medivir Q3 EBITDA Loss Narrows To SEK 22 Mln
Brief: Medivir Reports Results Of Phase IA Study Of MIV-818
Brief: Medivir Q2 EBITDA Loss Narrows To SEK 12.5 Mln
Brief: Medivir: MIV-818 Well-Tolerated By Patients, According To Phase Ia Study
Brief: Medivir: New Data From Phase I Study Of birinapant In Combination With Keytruda Presented At ASCO
Brief: Medivir: Positive Data From Remetinostat Phase II Study In Basal Cell Carcinoma
Brief: Medivir: Safety And Efficacy Data From MIV-711 Phase II Open Label Extension Study Presented At OARSI World Congress